Bimatoprost 0.01% · ophthalmic gel
Antiglaucoma
Approved uses
Open-angle glaucoma or ocular hypertension
One drop in the affected eye(s) once daily in the evening, and not more often
More frequent dosing lowers the effect rather than raising it, so once daily is a ceiling
Contraindications
Hypersensitivity to bimatoprost or to any of the ingredients
Bimatoprost ophthalmic gel 0.01%, 30 single-dose containers (0.3 g each)
Bimatoprost is a synthetic structural analog of prostaglandin that selectively mimics the effects of naturally occurring substances, prostamides. It is believed to lower intraocular pressure by increasing outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes.
Warnings & Precautions
- Pigmentation: Bimatoprost has been reported to cause changes to pigmented tissues, most often increased pigmentation of the iris, periorbital tissue (eyelid) and eyelashes. Iris pigmentation is likely to be permanent, while periorbital and eyelash changes have been reported to be reversible in some patients. Inform patients of the possibility of increased pigmentation; patients who develop noticeably increased iris pigmentation should be examined regularly.
- Eyelash changes: ZOLYMBUS may gradually increase the length, thickness and number of lashes and change vellus hair in the treated eye; these changes are usually reversible after stopping treatment.
- Intraocular inflammation: Prostaglandin analogs, including bimatoprost, have been reported to cause intraocular inflammation. Use with caution in patients with active intraocular inflammation (e.g., iritis/uveitis) because inflammation may be exacerbated.
- Macular edema: it has been reported with bimatoprost, including cystoid macular edema. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or with known risk factors for macular edema.
- Contact lens use: remove them before instilling ZOLYMBUS; they may be reinserted 15 minutes after administration.
Common Side Effects
In two clinical trials, the most frequently reported ocular adverse reactions were conjunctival hyperemia (14%), eye irritation (11%), eye pruritus (9%) and foreign body sensation in eyes (8%). Other adverse reactions, reported in 1% to 6% of patients, included dry eye, abnormal sensation in eye, lacrimation increased, eye pain, and vision blurred.
Pregnancy: There are no adequate and well-controlled studies of ZOLYMBUS in pregnant women. There is no increase in the risk of major birth defects or miscarriages based on bimatoprost post-marketing experience. In animal studies, oral bimatoprost during organogenesis resulted in abortion and early delivery at doses at least 33 times (mice) or 94 times (rats) the human exposure to bimatoprost solution 0.03% dosed bilaterally once daily. Use during pregnancy only if the potential benefit justifies the potential risk to the fetus.
Lactation: It is not known whether topical ocular treatment with ZOLYMBUS could result in sufficient systemic absorption to produce detectable quantities in human milk. Bimatoprost was present in the breast milk of lactating rats at an intravenous dose 970 times the recommended human ophthalmic dose; however, no animal data is available at clinically relevant doses. Consider the benefits of breastfeeding along with the mother's clinical need for ZOLYMBUS and any potential adverse effects on the breastfed child.
Use in patients below the age of 16 years is not recommended because of potential safety concerns related to increased pigmentation after long-term chronic use.